Equities
Health CareMedical Equipment and Services
  • Price (SEK)262.20
  • Today's Change-2.20 / -0.83%
  • Shares traded97.22k
  • 1 Year change+88.90%
  • Beta1.2019
Data delayed at least 15 minutes, as of Sep 19 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sectra AB is a Sweden-based technology company. It is operational through two business areas: Secure Communication Systems and Medical Systems. The Secure Communication Systems business area, which operates through the Company’s subsidiary Sectra Communications AB, delivers security solutions for customers who handle classified information, including government authorities, defense departments and critical functions of society throughout Europe. The Medical Systems business area, which operates through the subsidiary Sectra Imtec AB, offers information technology (IT) solutions, software licenses, service and upgrade agreements, online services, consultancy services and training courses to public and private healthcare providers. It has offices in 12 countries and operates through partners worldwide. As of April 30, 2012, the Company had six wholly owned direct subsidiaries, as well as 13 indirectly held wholly owned subsidiaries.

  • Revenue in SEK (TTM)1.81bn
  • Net income in SEK447.23m
  • Incorporated1957
  • Employees1.22k
  • Location
    Sectra ABTeknikringen 20LINKOPING 583 30SwedenSWE
  • Phone+46 13235200
  • Fax+46 13212185
  • Websitehttps://sectra.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revenio Group Oyj1.10bn215.80m10.49bn216.0048.059.2240.249.550.72050.72053.663.760.70695.507.60447,574.1013.9014.3316.7717.9051.0150.7319.6621.131.7928.490.152155.81-0.412525.80-12.1518.7217.676.30
Arjo AB (publ)11.23bn536.00m11.08bn6.94k22.151.497.160.98671.971.9741.2129.200.69574.406.511,651,221.003.313.554.515.5543.6844.014.765.410.66574.010.412343.0110.035.976.9010.15-8.8910.35
ChemoMetec A/S620.74m207.41m11.37bn173.0054.8113.2148.5018.317.837.8323.4432.480.61120.7456.972,357,630.0020.4227.9624.4035.1078.8079.5733.4135.023.76--0.0073144.08-8.2218.37-23.7226.649.97--
Biotage AB2.09bn250.00m14.49bn667.0057.973.8233.386.953.123.1226.0547.360.42371.706.603,094,956.005.0810.745.8712.7762.9061.4011.9815.751.1416.130.062840.1119.5415.50-8.217.9714.051.30
Xvivo Perfusion AB698.73m120.74m15.50bn152.00124.667.6581.8022.183.953.9522.6964.280.34411.224.484,367,031.005.951.246.451.3374.1673.1417.284.763.27--0.01330.0043.8826.04398.2948.5721.35--
Embla Medical hf8.37bn623.80m20.03bn4.00k32.212.6117.242.390.95570.955712.8111.800.56392.206.401,375,117.004.214.064.974.7661.8062.477.476.911.125.540.42053.999.335.0937.34-6.056.50--
Elekta AB (publ)18.12bn1.13bn25.32bn4.57k23.192.4510.971.402.962.9647.3828.010.58223.162.893,903,469.003.654.196.537.5136.7639.036.277.370.74253.910.419668.607.415.9838.071.6820.065.92
Vitrolife AB3.54bn-3.80bn32.21bn1.12k--2.46--9.11-28.06-28.0626.1196.720.18363.656.163,276,182.00-19.72-4.57-20.43-4.7857.4858.38-107.41-21.892.438.480.1379--8.6024.99-1,077.41---7.953.30
Sectra AB1.81bn447.23m47.86bn1.22k113.9030.7987.5126.442.322.329.408.590.6136--3.631,503,436.0015.1615.7528.0829.5247.0164.9524.7119.59----0.0270.0026.844.0614.2516.5848.37--
Ambu A/S8.01bn684.85m48.53bn4.82k80.236.2838.656.061.691.6919.8021.600.74592.187.171,140,165.006.383.817.374.6258.8859.378.555.431.5174.380.096122.897.4512.8880.65-13.006.67--
Getinge AB33.33bn2.58bn56.88bn11.89k23.601.9412.571.719.489.48122.36115.570.61682.487.042,839,084.004.815.316.356.9846.2747.837.798.690.64558.990.213637.8712.495.66-3.17---0.394434.49
Demant A/S34.05bn4.03bn95.09bn21.50k23.586.52--2.7911.9810.92101.2343.360.71922.035.681,034,778.008.528.2711.6813.2375.4574.1411.8511.341.065.580.62440.0013.8910.0012.236.968.80--
Data as of Sep 19 2024. Currency figures normalised to Sectra AB's reporting currency: Swedish Krona SEK

Institutional shareholders

39.35%Per cent of shares held by top holders
HolderShares% Held
Nordea Investment Management ABas of 31 Jul 202417.93m9.90%
SEB Investment Management ABas of 30 Aug 202414.42m7.96%
Fj�rde AP-fondenas of 31 Dec 20239.52m5.26%
AMF Fonder ABas of 30 Apr 20238.04m4.44%
The Vanguard Group, Inc.as of 04 Sep 20245.51m3.04%
Norges Bank Investment Managementas of 31 Dec 20233.71m2.05%
Cliens Kapitalf�rvaltning ABas of 30 Jun 20243.46m1.91%
Swedbank Robur Fonder ABas of 30 Aug 20243.32m1.84%
Brown Capital Management LLCas of 30 Jun 20243.15m1.74%
Lannebo Fonder ABas of 31 Dec 20232.16m1.20%
More ▼
Data from 31 Dec 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.